Status:
UNKNOWN
Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways
Lead Sponsor:
Gustave Roussy, Cancer Campus, Grand Paris
Conditions:
Cancer
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Multicentric interventional prospective study with collection of biological samples as part of a routine care research
Eligibility Criteria
Inclusion
- Age greater than or equal to 18 years.
- Male and female sex.
- Any patient with cancer (see list in the body of the protocol) requiring treatment by surgical resection and / or who will start treatment with mAb or BiTE.
- Patient information and signed informed consent.
- Subjects affiliated (or beneficiary) to a social security scheme
- Patients treated for immune complications by immunosuppressants may be included (corticosteroids, etc.).
Exclusion
- History of severe systemic autoimmune disease.
- Pregnant or breastfeeding patient
- Impossibility or refusal to sign informed consent
- Patient under guardianship or curatorship, or deprived of liberty by a judicial or administrative decision
Key Trial Info
Start Date :
September 8 2016
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2021
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT04349293
Start Date
September 8 2016
End Date
September 1 2021
Last Update
April 16 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Gustave Roussy
Villejuif, Val De Marne, France, 94800